Defining the ATA-2025 'consider RAIT' zone in older patients with N1b PTC.

ABSTRACT: The aim of this study was to quantify the cancer-specific death (CSD) benefit of radioactive iodine therapy (RAIT) in older patients with N1b differentiated thyroid carcinoma, a population designated by the ATA-2025 guideline as a 'consider RAIT' zone despite unproven mortality benefit, and to translate this recommendation into clinically actionable subgroups using a competing-risks framework. We used data from the Surveillance, Epidemiology, and End Results (SEER) programme (2004-2015) and analysed papillary thyroid carcinoma (PTC) cases aged ≥55 years with N1b, M0. After 1:1 propensity score matching, cumulative incidence function and Fine-Gray models evaluated associations between RAIT and CSD. Stratifications included tumour size, positive lymph node burden (PLN > 5), and ETE. A nomogr

SUBMITTER: Wang Z 

PROVIDER: S-EPMC12910568 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature